Can new vaccine technology confront drug-resistant bacterial infections?

Vaccine Insights 2023; 2(12), 465–469

DOI: 10.18609/vac.2023.62

Published: 5 January
Michael Super

Drug-resistant microbial infections are a growing problem—could next-generation vaccines be part of the solution? Casey Nevins, Assistant Editor, Vaccine Insightsspeaks with Michael Super, Director of ImmunoMaterials, Wyss Institute for Biologically Inspired Engineering, about ciVAXTM, a new broad-spectrum biomaterial vaccine platform targeting bacterial infections and septic shock.